Infliximab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Infliximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Infliximab Today - Breaking & Trending Today

Study: Early advanced therapy significantly improves Crohn's disease outcomes

A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve outcomes, including by reducing the number of people requiring urgent abdominal surgery for treatment of their disease by ten-fold. ....

United Kingdom , City Of , Toby Moore , Ruth Wakeman , University Of Cambridge , Cambridge Biomedical Research Centre , Department Of Medicine , Predictimmune Ltd , Care Research , Clinical Research Network , National Institute For Health , Cambridge University Hospitals , National Institute , Lancet Gastroenterology , Miles Parkes , Chief Investigator , Biomedical Research , Colitis United Kingdom , Year Six , Royal Free Hospital , Clinical Trial , Crohn 39s Disease , Digestive System , Immune System , Stomach Pain , Top Down ,

Marla Dubinsky, MD: Using Off-Label Treatments to Address the Unmet Need in Pediatric IBD

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals. ....

Marla Dubinsky , Drug Administration , Mount Sinai Kravis Children , Mount Sinai , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease , Anti Tnf ,

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab. ....

Sabyasachi Ghosh , Takeda Pharmaceuticals , Patients With Ulcerative Colitis , Outcomes From , Anti Tumor Necrosis Factor Therapy , Inflammatory Bowel , Front Med , Ulcerative Colitis , Inflammatory Bowel Disease , Dose Escalation , Loss Of Response , Antitumor Necrosis Factor Alpha Treatment , α4β7 Integrin Inhibitor ,

Charting the future of IBD treatment: From immune modulators to microRNA therapies

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care. ....

United States , United Kingdom , Jo Panuwatd Shutterstock , Inflammatory Bowel Disease , Immune Response , De Inhibitors , Small Molecules , Tumor Necrosis Factor , Tumor Necrosis Factor Alpha , Ulcerative Colitis ,

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477). ....

France General , Megan Craig , American College Of Rheumatology , American College , Anna Molto , Cochin Hospital , Inflammatory Arthritis , Tumor Necrosis Factor ,